JP2022526267A5 - - Google Patents
Info
- Publication number
- JP2022526267A5 JP2022526267A5 JP2021555448A JP2021555448A JP2022526267A5 JP 2022526267 A5 JP2022526267 A5 JP 2022526267A5 JP 2021555448 A JP2021555448 A JP 2021555448A JP 2021555448 A JP2021555448 A JP 2021555448A JP 2022526267 A5 JP2022526267 A5 JP 2022526267A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168231A JP2025000805A (ja) | 2019-03-15 | 2024-09-27 | ｋｃｎｔ１発現を低減するための化合物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819344P | 2019-03-15 | 2019-03-15 | |
| US62/819,344 | 2019-03-15 | ||
| US201962884501P | 2019-08-08 | 2019-08-08 | |
| US62/884,501 | 2019-08-08 | ||
| PCT/US2020/022680 WO2020190740A1 (en) | 2019-03-15 | 2020-03-13 | Compounds and methods for reducing kcnt1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168231A Division JP2025000805A (ja) | 2019-03-15 | 2024-09-27 | ｋｃｎｔ１発現を低減するための化合物及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022526267A JP2022526267A (ja) | 2022-05-24 |
| JP2022526267A5 true JP2022526267A5 (https=) | 2023-08-24 |
| JPWO2020190740A5 JPWO2020190740A5 (https=) | 2023-08-24 |
| JP7564817B2 JP7564817B2 (ja) | 2024-10-09 |
Family
ID=72520445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555448A Active JP7564817B2 (ja) | 2019-03-15 | 2020-03-13 | ｋｃｎｔ１発現を低減するための化合物及び方法 |
| JP2024168231A Pending JP2025000805A (ja) | 2019-03-15 | 2024-09-27 | ｋｃｎｔ１発現を低減するための化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168231A Pending JP2025000805A (ja) | 2019-03-15 | 2024-09-27 | ｋｃｎｔ１発現を低減するための化合物及び方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20220177893A1 (https=) |
| EP (1) | EP3938514A4 (https=) |
| JP (2) | JP7564817B2 (https=) |
| KR (1) | KR20210141983A (https=) |
| CN (3) | CN121674396A (https=) |
| AU (1) | AU2020241693B2 (https=) |
| BR (1) | BR112021015494A2 (https=) |
| CA (1) | CA3133247A1 (https=) |
| CL (1) | CL2021002398A1 (https=) |
| CO (1) | CO2021013371A2 (https=) |
| CR (1) | CR20210519A (https=) |
| IL (1) | IL285546A (https=) |
| JO (1) | JOP20210254A1 (https=) |
| MX (1) | MX2021011132A (https=) |
| PE (1) | PE20220168A1 (https=) |
| PH (1) | PH12021552220A1 (https=) |
| SG (1) | SG11202108625WA (https=) |
| TW (1) | TW202102675A (https=) |
| WO (1) | WO2020190740A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| MX2024006709A (es) * | 2021-12-01 | 2024-08-19 | Atalanta Therapeutics Inc | Composiciones y metodos para el tratamiento de epilepsias. |
| WO2025036916A1 (en) * | 2023-08-16 | 2025-02-20 | Les Laboratoires Servier | Oligonucleotides for modulating kcnt1 expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
| US7601501B2 (en) * | 2006-08-11 | 2009-10-13 | The Scripps Research Institute | Controlling osteogenesis by inhibition of osteogenic suppressors |
| EP3260540A1 (en) * | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| US20200129538A1 (en) | 2017-06-13 | 2020-04-30 | The Florey Institute Of Neuroscience And Mental Health | Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1 |
-
2020
- 2020-03-13 PE PE2021001518A patent/PE20220168A1/es unknown
- 2020-03-13 CR CR20210519A patent/CR20210519A/es unknown
- 2020-03-13 CN CN202511762645.3A patent/CN121674396A/zh active Pending
- 2020-03-13 CN CN202080020884.0A patent/CN113661241A/zh active Pending
- 2020-03-13 CA CA3133247A patent/CA3133247A1/en active Pending
- 2020-03-13 EP EP20773689.3A patent/EP3938514A4/en active Pending
- 2020-03-13 KR KR1020217032716A patent/KR20210141983A/ko not_active Withdrawn
- 2020-03-13 CN CN202311150264.0A patent/CN117106778A/zh active Pending
- 2020-03-13 MX MX2021011132A patent/MX2021011132A/es unknown
- 2020-03-13 WO PCT/US2020/022680 patent/WO2020190740A1/en not_active Ceased
- 2020-03-13 AU AU2020241693A patent/AU2020241693B2/en not_active Ceased
- 2020-03-13 BR BR112021015494-9A patent/BR112021015494A2/pt unknown
- 2020-03-13 JP JP2021555448A patent/JP7564817B2/ja active Active
- 2020-03-13 SG SG11202108625WA patent/SG11202108625WA/en unknown
- 2020-03-13 PH PH1/2021/552220A patent/PH12021552220A1/en unknown
- 2020-03-13 US US17/437,507 patent/US20220177893A1/en not_active Abandoned
- 2020-03-16 TW TW109108639A patent/TW202102675A/zh unknown
-
2021
- 2021-08-11 IL IL285546A patent/IL285546A/en unknown
- 2021-09-14 JO JOP/2021/0254A patent/JOP20210254A1/ar unknown
- 2021-09-14 CL CL2021002398A patent/CL2021002398A1/es unknown
- 2021-10-06 CO CONC2021/0013371A patent/CO2021013371A2/es unknown
-
2024
- 2024-09-27 JP JP2024168231A patent/JP2025000805A/ja active Pending
-
2025
- 2025-06-27 US US19/252,993 patent/US20250320505A1/en active Pending